Affinity Asset Advisors LLC cut its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 50.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,000 shares of the company's stock after selling 25,000 shares during the period. Affinity Asset Advisors LLC's holdings in Vaxcyte were worth $2,046,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Whipplewood Advisors LLC purchased a new stake in shares of Vaxcyte in the 4th quarter worth approximately $28,000. Smartleaf Asset Management LLC increased its holdings in shares of Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after purchasing an additional 260 shares during the period. National Bank of Canada FI purchased a new stake in shares of Vaxcyte in the 4th quarter valued at $41,000. Blue Trust Inc. grew its position in Vaxcyte by 100.0% during the 4th quarter. Blue Trust Inc. now owns 742 shares of the company's stock worth $61,000 after purchasing an additional 371 shares during the period. Finally, Assetmark Inc. raised its position in Vaxcyte by 77,500.0% during the fourth quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after acquiring an additional 775 shares in the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.
Vaxcyte Price Performance
Vaxcyte stock traded up $1.53 during trading hours on Friday, hitting $30.65. The stock had a trading volume of 1,724,222 shares, compared to its average volume of 1,220,251. The stock's fifty day moving average is $61.81 and its two-hundred day moving average is $83.64. The stock has a market capitalization of $3.95 billion, a price-to-earnings ratio of -6.66 and a beta of 1.26. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $121.06.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.14. As a group, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.
Analyst Ratings Changes
A number of equities analysts recently weighed in on PCVX shares. Guggenheim reaffirmed a "buy" rating and issued a $160.00 price target on shares of Vaxcyte in a report on Wednesday, March 12th. Bank of America lowered their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. The Goldman Sachs Group reduced their target price on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $90.00 price objective on shares of Vaxcyte in a research report on Tuesday, April 8th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $136.50.
Read Our Latest Analysis on Vaxcyte
Insider Buying and Selling
In other news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the sale, the chief operating officer now owns 154,931 shares of the company's stock, valued at approximately $11,351,794.37. The trade was a 4.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders have sold 32,000 shares of company stock valued at $2,638,800. Corporate insiders own 3.10% of the company's stock.
Vaxcyte Profile
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
See Also
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
